In the SGLT2i cohort (n = 38), insulin and DPP-4 inhibitors were more commonly maintained, with SGLT2i introduced as an add-on to existing regimens; this pattern is consistent with the substantial burden of heart failure in this subgroup (23/38, 60%), reflecting a therapeutic approach aimed at simultaneously optimizing glycemic control and cardiovascular risk. The gene discussed is DPP4; the disease is heart failure.